- Home
- HCKT vs TRDA Comparison
HCKT vs TRDA Comparison
Compare HCKT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- TRDA
- Stock Information
- Founded
- HCKT 1991
- TRDA 2016
- Country
- HCKT United States
- TRDA United States
- Employees
- HCKT N/A
- TRDA N/A
- Industry
- HCKT Professional Services
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- TRDA Health Care
- Exchange
- HCKT Nasdaq
- TRDA Nasdaq
- Market Cap
- HCKT 594.0M
- TRDA 609.7M
- IPO Year
- HCKT 1998
- TRDA 2021
- Fundamental
- Price
- HCKT $30.32
- TRDA $17.85
- Analyst Decision
- HCKT Strong Buy
- TRDA Strong Buy
- Analyst Count
- HCKT 3
- TRDA 3
- Target Price
- HCKT $30.00
- TRDA $23.33
- AVG Volume (30 Days)
- HCKT 128.2K
- TRDA 132.5K
- Earning Date
- HCKT 11-04-2024
- TRDA 11-05-2024
- Dividend Yield
- HCKT 1.09%
- TRDA N/A
- EPS Growth
- HCKT N/A
- TRDA N/A
- EPS
- HCKT 1.22
- TRDA 1.55
- Revenue
- HCKT $300,739,000.00
- TRDA $215,232,000.00
- Revenue This Year
- HCKT $8.66
- TRDA $47.63
- Revenue Next Year
- HCKT $5.16
- TRDA N/A
- P/E Ratio
- HCKT $24.85
- TRDA $11.51
- Revenue Growth
- HCKT 4.09
- TRDA 146.92
- 52 Week Low
- HCKT $20.23
- TRDA $10.75
- 52 Week High
- HCKT $32.34
- TRDA $20.49
- Technical
- Relative Strength Index (RSI)
- HCKT 65.70
- TRDA 48.42
- Support Level
- HCKT $24.06
- TRDA $19.28
- Resistance Level
- HCKT $32.34
- TRDA $20.49
- Average True Range (ATR)
- HCKT 0.92
- TRDA 0.92
- MACD
- HCKT 0.45
- TRDA -0.01
- Stochastic Oscillator
- HCKT 75.60
- TRDA 25.21
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP-based executive advisory, strategic consulting, and digital transformation firm. It provides Generative Artificial Intelligence ("Gen AI") strategy, operations, finance, human capital management, strategic sourcing, procurement, and information technology. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.